Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

12 czerwca 2019 zaktualizowane przez: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

876

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Chiny
      • Beijing, Chiny, 100050
        • Novartis Investigative Site
      • Chongqing, Chiny, 400037
        • Novartis Investigative Site
      • Shanghai City, Chiny
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, Chiny, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, Chiny, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, Chiny, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Chiny, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, Chiny, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, Chiny, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, Chiny
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, Chiny, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, Chiny, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, Chiny, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, Chiny, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Chiny, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, Chiny, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Chiny, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Chiny, 325000
        • Novartis Investigative Site
  • Filipiny
      • Makati City, Filipiny, 1229
        • Novartis Investigative Site
      • Manila, Filipiny, 1003
        • Novartis Investigative Site
      • Pasig City, Filipiny, 1605
        • Novartis Investigative Site
      • Quezon City, Filipiny, 1102
        • Novartis Investigative Site
      • Quezon City, Filipiny, 1113
        • Novartis Investigative Site
      • San Juan City, Filipiny, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, Filipiny, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Filipiny, 1000
        • Novartis Investigative Site
  • Indie
      • Rajasthan, Indie, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, Indie, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Indie, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, Indie, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, Indie, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Indie, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indie, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indie, 500082
        • Novartis Investigative Site
  • Japonia
      • Osaka, Japonia, 534-0021
        • Novartis Investigative Site
      • Saitama, Japonia, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, Japonia, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, Japonia, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, Japonia, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, Japonia, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, Japonia, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, Japonia, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japonia, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japonia, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, Japonia, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japonia, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japonia, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, Japonia, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, Japonia, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Japonia, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, Japonia, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, Japonia, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, Japonia, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, Japonia, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, Japonia, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, Japonia, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, Japonia, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, Japonia, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonia, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonia, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonia, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, Japonia, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, Japonia, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, Japonia, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, Japonia, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, Japonia, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, Japonia, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, Japonia, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, Japonia, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, Japonia, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, Japonia, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, Japonia, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, Japonia, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, Japonia, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, Japonia, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, Japonia, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, Japonia, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, Japonia, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, Japonia, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, Japonia, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, Japonia, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Japonia, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, Japonia, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, Japonia, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, Japonia, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, Japonia, 646-8558
        • Novartis Investigative Site
  • Jordania
      • Amman, Jordania, 11183
        • Novartis Investigative Site
      • Amman, Jordania, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, Jordania, 11152
        • Novartis Investigative Site
  • Liban
      • Ashrafieh, Liban, 166830
        • Novartis Investigative Site
      • Beirut, Liban, 1107 2020
        • Novartis Investigative Site
      • Beirut, Liban
        • Novartis Investigative Site
      • Hazmieh, Liban, 470
        • Novartis Investigative Site
  • Malezja
      • Kuala Lumpur, Malezja, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, Malezja, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, Malezja, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, Malezja, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malezja, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, Malezja, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, Malezja, 47000
        • Novartis Investigative Site
  • Republika Korei
      • Busan, Republika Korei, 602739
        • Novartis Investigative Site
      • Gwangju, Republika Korei, 61469
        • Novartis Investigative Site
      • Incheon, Republika Korei, 405 760
        • Novartis Investigative Site
      • Seoul, Republika Korei, 03080
        • Novartis Investigative Site
      • Seoul, Republika Korei, 03722
        • Novartis Investigative Site
      • Seoul, Republika Korei, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, Republika Korei, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, Republika Korei, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, Republika Korei, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, Republika Korei, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Republika Korei, 05505
        • Novartis Investigative Site
      • Seoul, Korea, Republika Korei, 06351
        • Novartis Investigative Site
      • Seoul, Korea, Republika Korei, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, Republika Korei, 06591
        • Novartis Investigative Site
  • Singapur
      • Singapore, Singapur, 169609
        • Novartis Investigative Site
      • Singapore, Singapur, 117549
        • Novartis Investigative Site
  • Tajlandia
      • Bangkok, Tajlandia, 10330
        • Novartis Investigative Site
      • Bangkok, Tajlandia, 10700
        • Novartis Investigative Site
      • Bangkok, Tajlandia, 10400
        • Novartis Investigative Site
      • Chiang Mai, Tajlandia, 50200
        • Novartis Investigative Site
      • Muang, Tajlandia, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Tajlandia, 90110
        • Novartis Investigative Site
  • Tajwan
      • Changhua, Tajwan, 50006
        • Novartis Investigative Site
      • Kaohsiung, Tajwan, 80756
        • Novartis Investigative Site
      • Kaohsiung City, Tajwan, 83301
        • Novartis Investigative Site
      • New Taipei, Tajwan, 22060
        • Novartis Investigative Site
      • Taichung, Tajwan, 40447
        • Novartis Investigative Site
      • Taipei, Tajwan, 10002
        • Novartis Investigative Site
      • Taipei, Tajwan, 11217
        • Novartis Investigative Site
      • Taipei, Tajwan, 10449
        • Novartis Investigative Site
      • Taoyuan, Tajwan, 33305
        • Novartis Investigative Site
      • Yilan, Tajwan, 26058
        • Novartis Investigative Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Lek: Placebo
Infuzja dożylna
Inny: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Eksperymentalny: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
Inny: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Lek: Serelaksyna
Infuzja dożylna

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
Ramy czasowe: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Time to WHF
Ramy czasowe: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
Ramy czasowe: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
Ramy czasowe: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
Ramy czasowe: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
Ramy czasowe: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
Ramy czasowe: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
Ramy czasowe: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
Ramy czasowe: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
Ramy czasowe: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
Ramy czasowe: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
Ramy czasowe: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
Ramy czasowe: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
Ramy czasowe: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Novartis Pharmaceuticals

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 marca 2014

Zakończenie podstawowe (Rzeczywisty)

27 marca 2017

Ukończenie studiów (Rzeczywisty)

16 czerwca 2017

Daty rejestracji na studia

Pierwszy przesłany

20 listopada 2013

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 grudnia 2013

Pierwszy wysłany (Oszacować)

11 grudnia 2013

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

2 sierpnia 2019

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 czerwca 2019

Ostatnia weryfikacja

1 czerwca 2019

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • CRLX030A2302

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Ostra niewydolność serca

Badania kliniczne na Placebo

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Qatar

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj